

New Benzylpiperazine Derivatives Bearing Mono- and Bis-dialkyl Substituted 1,2,4-Triazoles

Yaseen A. Al-Soud,¹ Mohammed N. A. Qalalweh,¹
Haitham H. Al-Sa'doni,¹ and Najim A. Al-Masoudi²

¹Department of Chemistry, College of Science, University of Al al-Bayt, Al-Mafraq, Jordan

²Formerly Fachbereich Chemie, Universität Konstanz, Postfach 5560, D-78457 Konstanz, Germany

Received 23 August 2004; revised 22 September 2004

ABSTRACT: Cycloaddition of the 1-aza-2-azoniaallenes **3** with *p*-cyanobenzyl chlorides afforded, after spontaneous rearrangement, the 1,5-dialkyl-3-[4-chloromethyl]phenyl]-1H-[1,2,4]-triazoles **6**. A series of 1,5-dialkyl-1H-[1,2,4]-triazol-3-yl)benzylpiperazines **7** and **8** were prepared from direct condensation of **6** with piperazine and *N*-methylpiperazine, respectively. The structures of the newly synthesized products were identified by 2D NMR spectroscopy. © 2005 Wiley Periodicals, Inc. *Heteroatom Chem* 16:28–32, 2005; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hc.20061

INTRODUCTION

Several heterocycles containing piperazines residues have been described as potent chemotherapeutic agents. Recently, some compounds bearing piperazines residue were described as highly specific inhibitory of HIV-1 replication, such as bis-(indolyl)-piperazine (BHAP) [4] and trovirdine derivative [5]. Other various 1,2-dialkyl piperazines have been reported as antibacterial [6–8], antiprotozoacidal [9], antihypertensive [10,11], coronary dilators [12], H-3 antagonists [13], such as the antipsychotic

agent clozapine [14], tryptase inhibitors [15,16], antiplatelet agents with antivasodilatory effect [17], sedative and tranquilizers [18], antihelminthic and antifilarial agents [19], antineoplastic agents [7,20,21], as well as antagonist of postsynaptic receptors 5-HT1A [22,23]. The pharmacological potency of such substituted piperazines, as well as the biological activity of 1,2,4-triazole analogues such as fluconazole [24] prompted us to prepare a new series of 1,4-disubstituted piperazines carrying substituted 1,2,4-triazoles and/or methyl group, as potential antitumor candidates.


RESULTS AND DISCUSSION

Recently, the 4,5-dihydro-3H-pyrazolium salts have been synthesized from the cycloaddition of the short-lived 1-(chloroalkyl)-1-aza-2-azoniaallene hexachloroantimonates **3** [25–27] to various electron-rich alkenes in the presence of Lewis acids like SbCl₅; similarly numerous compounds of 1,2,4-triazoles were prepared recently in our laboratory *via* the cycloaddition of the nitrile derivatives to intermediates **3**. Such examples of our recent work are 1,2,4-triazole *C*-nucleosides [28,29], acyclic *C*-nucleosides [30], pyrimidines [31], *N*-alkylphthalimides [32], *D*-manno-pentitol-1-yl-1,2,4-triazoles [33], 1H-indoles as well as quinolines [34], benzotriazoles [35], 3'-triazolothymidines [36], *N,N'*-trisubstituted 1,2,4-triazolo-piperazines [37], and 1,2,4-triazole derivatives

Correspondence to: Najim A. Al-Masoudi; e-mail: Najim.Al-Masoudi@gmx.de.
© 2005 Wiley Periodicals, Inc.

of acetic acid alkylidene hydrazides [38]. In the present study, we prepared the 3-[4-(chloromethyl)-phenyl]-1,5-dimethyl-1*H*-1,2,4-triazole **6a** and **6c**, according to our reported method during the preparation of **6b** and **6d** [34], from the cycloaddition of **3** to 4-cyanobenzyl chloride **1**. Thus, the dichlorides **2** were converted, at approximately -60°C , to the salts **3** in the presence of SbCl_5 . At -30°C , the color changed indicating that **3** underwent cycloaddition with the nitrile **1** to give the inseparable 5-[4-(chloromethyl)-phenyl]-3*H*-1,2,4-triazolium hexachloroantimonates **4**. As the temperature was raised above -30°C , **4** rearranged to protonated triazole **5** by [1,2] migration [39,40] of the alkyl group (R^2) at C-3 to N-2, accompanied by elimination of the CClR^1R^2 group. In situ hydrolysis of **5** with aqueous NaHCO_3 and aqueous NH_3 afforded the triazoles **6a** and **6c** in 65 and 73% yield, respectively.

Next, condensation of **6a–d** with piperazine in the ratio of (2:1) in the presence of NaH or K_2CO_3 and DMF at 25°C for 48 h afforded, after recrystallization from the appropriate solvent, the desired products of 1,4-bis-(1,5-dialkyl-1*H*-[1,2,4]-triazol-3-ylbenzyl)-piperazines **7a–d** in 85–87% yield (Scheme 1). These compounds were identified by homo- and heteronuclear NMR spectroscopic methods, HMBC [41], and mass spectra. The ^1H NMR spectra of **7a–d** showed similar patterns. The $\text{CH}_2\text{-1'}$ appeared as singlets at δ 3.53, 3.61, 3.54, and 3.55, respectively. The two doublets at δ 7.97, 7.42 (8.2 Hz); 7.99, 7.38 (8.1 Hz); 8.00, 7.37 (7.7 Hz), and 7.97, 7.35 (8.2 Hz), respectively, were attributed for the symmetrical four aromatic protons. The alkyl groups at N-1'' and C-5'' were assigned. The ^{13}C NMR spectra of **7a–d** contained the resonance signals of the triazole carbons ring (C-3'', C-5'' of **7a,b**) and (C-2'', C-10'' of **7c,d**) at higher fields



SCHEME 1 Reagents and conditions: i. **2**, SbCl_5 , CH_2Cl_2 , -60°C ; ii. CH_2Cl_2 , -60°C to 23°C ; iii. NaHCO_3 , NH_3 , MeCN , 0°C , 2h; iv. piperazine, NaH or K_2CO_3 ; v. methylpiperazine K_2CO_3 , DMF.

between δ 159.5–161.5 and δ 151.8–157.8, respectively. Due to the identical groups attached at N-1 and N-4, the carbon atoms of piperazine ring of **7a–d** appeared as broad singlets at δ 53.1, 53.1, 51.4, and 51.1, respectively. Compound **7d** was selected for this NMR study showing a $^3J_{\text{C,H}}$ between C-10'' at δ 157.8 and CH₂-5'' at δ 4.18, as well as a $^2J_{\text{C,H}}$ between Ar-quart. C at 138.7 and CH₂-1' at δ 3.53. An obvious $^3J_{\text{C,H}}$ correlation was shown between C-5'' at δ 53.0 and CH₂-7'' at δ 1.77, as well. The antitumor activity is under investigation.

Similarly, the 1-(1,5-dialkyl-1H-[1,2,4]-triazol-3-yl)benzyl-4-methylpiperazines **8a–d** were prepared from condensation of **6** with *N*-Me-piperazine in DMF as a solvent and K₂CO₃ for 48 h at 25°C in 28, 33, 40, 29% yields, respectively (Scheme 1).

EXPERIMENTAL [28–37]

Preparation of 1,5-dialkyl-3-[4-chloromethyl-phenyl]-1H-[1,2,4]-triazoles (**6**)

To a stirred, cooled (–60°C) solution of **2** (5.0 mmol) and **1** (0.76 g, 5.0 mmol) in dry CH₂Cl₂ (20 mL) was added dropwise a solution of SbCl₅ (4.20 g, 5.0 mmol) in dry CH₂Cl₂ (20 mL). The solution was left with stirring at –60°C for 1 h, then at 0°C for 1 h, and finally at 23°C for 10 min, followed by addition of pentane (50 mL). The precipitated solid was dissolved in CH₃CN (40 mL), cooled to 0°C followed by addition of an aqueous solution of NaHCO₃ (2.55 g, 30 mmol in 30 mL of water) and NH₃ solution (2 mL). The mixture was stirred at room temperature for 2 h, then the organic solvent was evaporated and the residue was extracted with CHCl₃ (3 × 20 mL). The combined organic extracts were dried (Na₂SO₄), filtered, and evaporated to dryness and the residue was recrystallized from petroleum ether.

3-[4-(Chloromethyl)phenyl]-1,5-dimethyl-1H-1,2,4-triazole (**6a**). From **2a** (0.92 g). Yield: 0.72 g (65%); mp 150–155°C. ¹H-NMR (CDCl₃): δ 8.03 (d, 2H, *J* = 8.5 Hz, Ar); 7.43 (s, 2H, *J* = 8.4 Hz, Ar); 4.60 (s, 2H, CH₂-1'); 3.83 (s, 3H, N-Me); 2.49 (s, 3H, C₅-Me). ¹³C-NMR (CDCl₃): δ 159.7 (C-3''); 152.9 (C-5''); 139.6, 128 (Ar-2 × C), 129.3 (Ar-2 × C); 127.8 (Ar-C); 126.4 (Ar-C); 45.9 (C-1'); 35.2 (N-CH₃); 11.7 (C₅-CH₃). Anal. calc. for C₁₁H₁₂ClN₃ (221.69): C, 59.60; H, 5.46; N, 18.95. Found: C, 59.31; H, 5.32; N, 18.73; MS: *m/z* (%) (EI) 220/222 (80).

2-[4-(Chloromethyl)phenyl]-5,6,7,8-tetrahydro-[1,2,4]-triazolo[1,5-*a*]pyridine (**6c**). From **2c** (1.18 g). Yield: 0.90 g (73%); mp 110–115°C. ¹H-NMR (CDCl₃): δ 8.12 (d, 2H, *J* = 8.0 Hz, Ar); 7.47 (s, 2H, *J* = 8.0

Hz, Ar); 4.18 (t, 2H, *J* = 6.0 Hz, CH₂-5''); 4.27 (s, 2H, CH₂-1'); 3.28 (t, 2H, *J* = 6.1 Hz, CH₂-6''); 2.20 (m, 2H, CH₂-7''); 2.07 (m, 2H, CH₂-8''). ¹³C-NMR (CDCl₃): 153.9 (C-2''); 152.1 (C-10''); 140.8, (Ar-C); 129.1 (Ar-2 × C); 128.7 (Ar-C); 127.3 (Ar-2 × C); 47.99 (C-5''); 45.3. (C-1'); 21.9 (C-7''); 21.7 (C-6''); 18.3 (C-8''). Anal. calc. for C₁₃H₁₄ClN₃ (247.72): C, 63.03; H, 5.70; N, 16.96. Found: C, 62.82; H, 5.61; N, 16.67; MS: *m/z* (%) (EI) 246/248 (85).

Preparation of 1,4-bis-[(1,5-dialkyl-1H-[1,2,4]-triazol-3-yl)benzyl]-piperazines (**7**)

To a solution of piperazine (0.086 g, 1.00 mmol) in DMF (7 mL) was stirred K₂CO₃ (0.22 g, 2.10 mmol) and stirred for 3 min at 25°C, followed by addition of **6** (2.10 mmol). After stirring at 25°C for 48 h, the solvent was evaporated to dryness and the residue was partitioned between CH₂Cl₂ (40 mL) and water (20 mL) and the organic layer was dried (Na₂SO₄), filtered, and evaporated to dryness. The residue was stirred with petroleum ether and filtered, dried to give **7** as a pure solid.

1,4-Bis-[(1,5-dimethyl-1H-[1,2,4]-triazol-3-yl)benzyl]-piperazine (**7a**). From **6a** (0.46 g). Yield: 0.82 g (85%); mp 250–255°C, decomp. at 267°C. ¹H-NMR (CDCl₃): δ 7.97 (d, 2H, *J* 8.2 Hz, Ar); 7.42 (s, 2H, *J* 8.2 Hz, Ar); 3.84 (s, 3H, N-Me); 3.53 (s, 2H, CH₂-1'); 2.49 [br s, 11H, 4 × (CH₂) of piperazine; C₅-Me]. ¹³C-NMR (CDCl₃): δ 161.5 (C-3''); 152.7 (C-5''); 139.1, 129.9 (Ar-2 × C), 129.3 (Ar-2 × C); 127.3 (Ar-C); 125.9 (Ar-C); 62.8 (C-1'); 53.1 (4 × C-piperazine); 35.1 (N-CH₃); 11.8 (C₅-CH₃). Anal. calc. for C₂₆H₃₂N₈ (456.59): C, 68.39; H, 7.06; N, 24.54. Found: C, 67.91; H, 6.89; N, 24.48; MS: *m/z* (%) (EI) 456 (90).

1,4-Bis-(1-ethyl-5-methyl-1H-[1,2,4]-triazol-3-yl)benzyl]-piperazine (**7b**). From **6b** (0.49 g). Yield: 0.86 g (85%); mp 200–205°C. ¹H-NMR (CDCl₃): δ 7.99 (d, 2H, *J* = 8.1 Hz, Ar); 7.38 (d, 2H, *J* 8.1 Hz, Ar); 4.14 (q, 2H, *J* = 7.0 Hz, CH₂CH₃); 3.81 (s, 3H, N-Me); 3.61 (s, 2H, CH₂-1'); 2.59 [br s, 8H, 4 × (CH₂) of piperazine]; 1.48 (t, 3H, CH₂CH₃). ¹³C-NMR (CDCl₃): δ 160.6 (C-3''); 151.8 (C-5''); 139.0, 130.1, 129.3 (4 × C); 127.8, 125.9 (2 × C); 62.8 (C-1'); 53.1 (4 × C-piperazine); 43.3 (CH₂CH₃); 14.1 (CH₂CH₃); 11.8 (C₅-Me). Anal. calc. for C₂₈H₃₆N₈ (484.64): C, 69.39; H, 7.49; N, 23.12. Found: C, 69.02; H, 7.34; N, 22.95; MS: *m/z* (%) (EI) 484 (80).

1,4-Bis-[(5,6,7,8-tetrahydro-1H-[1,2,4]triazolo-[1,5-*a*]pyridin-2-yl)benzyl]-piperazine (**7c**). From **6c** (0.52 g). Yield: 0.90 g (85%); mp 270–275°C, decomp.

at 315°C. ¹H-NMR (CDCl₃): δ 8.00 (d, 2H, *J* = 7.7 Hz, Ar); 7.37 (d, 2H, *J* = 7.7 Hz, Ar); 4.18 (t, 2H, *J* = 6.0 Hz, CH₂-5''); 3.54 (s, 2H, CH₂-1'); 2.97 (t, 2H, *J* = 6.0 Hz, CH₂-6''); 2.51 [br s, 8H, 4 × (CH₂) of piperazine]; 2.09 (m, 2H, CH₂-7''); 2.00 (m, 2H, CH₂-8''). ¹³C-NMR (CDCl₃): δ 159.5 (C-2''); 151.5 (C-10''); 137.4, 130.0 (Ar-2 × C); 127.7, 127.6 (Ar-2 × C); 124.4 (Ar-2 × C); 61.2 (C-1'); 51.4 (4 × C-piperazine); 45.4 (C-5''); 22.1 (C-7''); 21.3 (C-6''); 18.9 (C-8''). Anal. calc. for C₃₀H₃₆N₈ (508.67): C, 70.84; H, 7.13; N, 22.03. Found: C, 70.62; H, 6.97; N, 21.74; MS: *m/z* (%) (EI) 508 (50).

1,4-Bis-[(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[1,5-a]azepin-2-yl)benzyl]-piperazine (7d). From **6d** (0.55 g). Yield: 0.98 g (87%); mp 280–285°C. ¹H-NMR (CDCl₃): δ 7.97 (d, 2H, *J* = 8.2 Hz, Ar); 7.35 (d, 2H, *J* = 8.2 Hz, Ar); 4.29 (t, 2H, *J* = 5.2 Hz, CH₂-5''); 3.53 (s, 2H, CH₂-1'); 2.97 (t, 2H, *J* = 6.4 Hz, CH₂-6''); 2.49 [br s, 8H, 4 × (CH₂) of piperazine]; 1.87 (t, 2H, *J* = 7.5 Hz, CH₂-8''); 1.80 (m, 2H, CH₂-9''); 1.77 (t, 2H, *J* = 5.2 Hz, CH₂-7''). ¹³C-NMR (CDCl₃): δ 159.5 (C-2''); 157.8 (C-10''); 138.7, 129.3 (Ar-2 × C); 129.1 (Ar-C); 127.3 (Ar-C); 125.8 (Ar-2 × C); 62.8 (C-1'); 53.0 (C-5''); 51.1 (C-piperazine); 30.3 (C-7''); 27.5 (C-6''); 27.4 (C-9''); 25.0 (C-8''). Anal. calc. for C₃₂H₄₀N₈ (536.7): C, 71.61; H, 7.51; N, 20.88. Found: C, 71.40; H, 7.39; N, 19.54; MS: *m/z* (%) (EI) 536 (45).

Preparation of 1-[(1,5-dialkyl-1H-[1,2,4]-triazol-3-yl)benzyl]-4-methylpiperazines (**8a,b,d**)

To a solution of methylpiperazine (0.20 g, 2.00 mmol) in DMF (3 mL) at ~−10°C was stirred with NaH (0.08 g, 2.00 mmol) for 15 min, followed by addition of **6** (2.00 mmol). After stirring for 3 h at −10°C, and for 48 h at 25°C, the solvent was evaporated to dryness and the residue was partitioned between CH₂Cl₂ (50 mL) and water (25 mL) and the organic layer was dried (Na₂SO₄), filtered, and evaporated to dryness. The residue was taken by petroleum ether to give **8** as a pure solid.

1-[(1,5-Dimethyl-1H-[1,2,4]-triazol-3-yl)benzyl]-4-methylpiperazine (8a). From **6a** (0.44 g). Yield: 0.16 g (28%); mp 170–174°C. ¹H-NMR (CDCl₃): δ 8.00 (d, 2H, *J* 7.6 Hz, Ar); 7.42 (s, 2H, *J* 7.6 Hz, Ar); 3.78 (s, 3H, N-Me-triazole), 3.50 (s, 2H, CH₂-1'); 2.50 [br s, 8H, 4 × (CH₂) of piperazine]; 2.37 (br s, 6H, N-Me-piperazine, C₅-Me). ¹³C-NMR (CDCl₃): δ 160.5 (C-3'); 153.0 (C-5'); 138.6, 130.3 (Ar-2 × C), 129.2 (Ar-2 × C); 126.3 (Ar-C); 125.9 (Ar-C); 61.6 (C-1'); 53.6; 52.0 (4 × C-piperazine); 43.4 (N-Me-piperazine); 35.2 (N-Me); 11.8 (C₅-Me). Anal. calc. for C₁₆H₂₃N₅

(285.4): C, 67.34; H, 8.12; N, 24.54. Found: C, 66.96; H, 8.04; N, 24.28; MS: *m/z* (%) (EI) 285 (50).

1-[(1-Ethyl-5-methyl-1H-[1,2,4]-triazol-3-yl)-benzyl]-4-methylpiperazine (8b). From **6b** (0.46 g). Yield: 0.20 (33%); mp 78–80°C. ¹H-NMR (CDCl₃): δ 7.93 (d, 2H, *J* = 8.1 Hz, Ar); 7.30 (s, 2H, *J* = 8.1 Hz, Ar); 4.10 (q, 2H, *J* = 7.1 Hz, N-CH₂CH₃); 3.45 (s, 2H, CH₂-1'); 2.48 [br s, 8H, 4 × (CH₂) of piperazine]; 2.42 (s, 3H, N-Me-piperazine), 2.29 (s, 3H, C₅-Me); 1.40 (t, 3H, N-CH₂CH₃). ¹³C-NMR (CDCl₃): δ 160.5 (C-3'); 151.9 (C-5'); 138.7, 130.2 (Ar-2 × C), 129.3 (Ar-2 × C); 126.0 (Ar-C); 125.9 (Ar-C); 62.7 (C-1'); 54.9, 52.6 (4 × C-piperazine); 44.2 (N-Me-piperazine); 43.4 (C₅-CH₂CH₃); 15.2 (C₅-CH₂CH₃); 11.9 (C₅-CH₃). Anal. calc. for C₁₇H₂₅N₅ (299.4): C, 68.19; H, 8.42; N, 23.39. Found: C, 67.87; H, 8.31; N, 23.10; MS: *m/z* (%) (EI) 299 (95).

1-[(5,6,7,8-Tetrahydro-1H-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzyl]-4-methylpiperazine (8c). To a suspension of methylpiperazine (0.20 g, 2.00 mmol) in EtOH (10 mL) was added Na₂CO₃ (0.21 g, 2.00 mmol), followed by addition of **6c** (0.50 g, 2.00 mol). After stirring at 25°C for 48 h, the solvent was evaporated to dryness, and the residue was worked-up as in 'method a' to give **8c** (0.25 g, 40%), as a yellow solid; mp 250–254°C. ¹H-NMR (CDCl₃): δ 7.99 (d, 2H, *J* = 8.0 Hz, Ar); 7.37 (d, 2H, *J* = 8.0 Hz, Ar); 4.18 (br s, 2H, CH₂-9''); 3.53 (s, 2H, CH₂-1'); 2.96 (br s, 2H, CH₂-6''); 2.51 [br s, 8H, 4 × (CH₂) of piperazine]; 2.39 (s, 3H, N-Me-piperazine), 2.09 (m, 2H, CH₂-7''); 2.01 (m, 2H, CH₂-8''). ¹³C-NMR (CDCl₃): δ 161.1 (C-2''); 153.0 (C-9''); 139.7, 130.2 (Ar-2 × C); 129.3 (Ar-2 × C); 126.0 (Ar-2 × C); 62.8 (C-1'); 53.0, 51.5 (4 × C-piperazine); 45.2 (N-Me-piperazine); 45.3 (C-5''); 23.6 (C-7''); 22.9 (C-6''); 20.5 (C-8''). Anal. calc. for C₁₈H₂₅N₈ (311.4): C, 69.42; H, 8.09; N, 22.49. Found: C, 69.11; H, 7.89; N, 22.05; MS: *m/z* (%) (EI) 311 (65).

1-[(6,7,8,9-Tetrahydro-5H-[1,2,4]triazolo[1,5-a]azepin-2-yl)benzyl]-4-methylpiperazine (8d). From **6d** (0.52 g). Yield: 0.19 g (29%); mp 111–113°C. ¹H-NMR (CDCl₃): δ 8.0 (d, 2H, *J* = 8.0 Hz, Ar); 7.35 (s, 2H, *J* = 8.0 Hz, Ar); 4.30 (m, 2H, CH₂-10''); 3.55 (s, 2H, CH₂-1'); 3.02 (t, 2H, *J* = 6.5 Hz, CH₂-6''); 2.59 [br s, 8H, 4 × (CH₂) of piperazine]; 2.38 (s, 3H, N-Me-piperazine); 1.95 (m, 2H, CH₂-8''); 1.88 (m, 2H, CH₂-9''); 1.78 (m, 2H, CH₂-7''). ¹³C-NMR (CDCl₃): δ 159.4 (C-2''); 157.9 (C-10''); 139.7, 130.6 (Ar-2 × C); 129.3 (Ar-2 × C); 126.0 (Ar-2 × C); 62.2 (C-1'); 54.9, 52.9 (4 × C-piperazine); 51.2 (C-5''), 44.6 (N-Me-piperazine); 30.4 (C-7''); 27.6 (C-6''); 27.4 (C-9''); 25.0 (C-8''). Anal. calc. for C₁₉H₂₇N₅ (325.4):

C, 70.12; H, 8.36; N, 21.52. Found: C, 69.89; H, 8.18; N, 21.18; MS: m/z (%) (EI) 325 (98).

REFERENCES

- [1] Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J. A.; Quintero, J. C.; Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; Graham, P. I.; Condra, J.; Gotlib, H.; Holloway, M. K.; Lin, J. H.; Chen, I.-W.; Vastag, K.; Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. *Proc Natl Acad Sci USA* 1994, 91, 4096–4100.
- [2] Dorsey, B. D.; Levin, R. B.; McDaniel, S. L.; Vacca, J. P.; Guare, J. P.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Lin, J. H.; Chen, I.-W.; Holloway, M. K.; Fitzgerald, P. M. D.; Axel, M. G.; Ostovic, D.; Anderson, P. S.; Huff, J. R. *J Med Chem* 1994, 37, 3443–3451.
- [3] Romero, D. L.; Morge, R. A.; Biles, C.; Berriospena, T. N.; May, P. D.; Palmer, J. R. Johnson, P. D.; Smith, H. W.; Busso, M.; Tan, C. K.; Voorman, R. L.; Reusser, F.; Althaus, I. W.; Downey, K. M.; So, A. G.; Resnick, L.; Tarpley, W. G.; Aristoff, P. A. *J Med Chem* 1994, 37, 999–1014.
- [4] Romero, D. L.; Busso, M.; Tan, C. K.; Reusser, F.; Palmer, J. R.; Poppe, S. M.; Aristoff, P.; Downey, K. M.; So, A. G.; Resnick, L.; Tarpley, W. G.; *Proc Natl Acad Sci USA* 1991, 88, 8806–8810.
- [5] Vig, R.; Mao, C.; Venkatachalam, T. K.; Tuel-Ahlgren, L.; Sudbeck, E. A.; Uckun, F. M. *Bioorg Med Chem* 1998, 6, 1789–1797.
- [6] Tucker, J. A.; Allwine, D. A.; Grega, K. C.; Barbachyn, M. R.; Klock, J. L.; Adamski, J. L. *J Med Chem* 1998, 41, 3727–3735.
- [7] Malinka, W. *Pharmazie* 2002, 56, 384–389.
- [8] Malinka, W.; Sieklicka-Dziuba, M.; Rajtjar, G.; Zgodzinski, Z.; Kleinrok, Z. *Pharmazie* 2000, 55, 416–425.
- [9] Winkelmann, E.; Raether, W. *Farbwerke Hoechst A.-G.*, (1994) *Ger. Offen.* 2,308,826 (Cl. Ci 07c) p 23 08 826.8-44, 10 pp.
- [10] Da Settimo, A.; Ferrarini, P. L.; Mori, C.; Primofiore, G. *Farmaco* 1986, 41, 926–933.
- [11] Archibald, J. L.; Freed, M. E. *J Med Chem* 1974, 17, 745–747.
- [12] Beyerle, R.; Stachel, A.; Nitz, R. E.; Resag, K.; Schraven, B.; Ritter, H. Cassella, *Farbwerke Mainkur A.-G.* (1968) *Ger. Offen.* 1,135,907 (Cl. C 07d) *Chem Abst* 1969, 71, 49978e.
- [13] Shah, C.; McAtee, L.; Breitenbucher, J. G.; Rudolph, D.; Li, X.; Lovenberg, T. W.; Mazur, C.; Wilson, S. J.; Carruthers, N. I. *Bioorg Med Chem Lett* 2002, 12, 3309–3312.
- [14] van Tol, H. H. M.; Bunzow, J. R.; Guan, H.-C.; Sunahara, R. K.; Seeman, P.; Niznik, H. B. *Nature* 1991, 350, 610–614.
- [15] Sutton, J. C.; Bolton, S. A.; Hartl, K. S.; Huang, M.-H.; Jacobs, G.; Meng, W.; Ogletree, M. L.; Pi, Z.; Schumacher, W. A.; Seiler, S. M.; Slusarchyk, W.; Treuner, U.; Zahler, R.; Zhao, G.; Bisacchi, G. *Bioorg Med Chem Lett* 2002, 12, 3229–3233.
- [16] Slusarchyk, W. A.; Bolton, S. A.; Hartl, K. S.; Huang, M.-H.; Jacobs, G.; Meng, W.; Ogletree, M. L.; Pi, O. Z.; Schumacher, W. A.; Seiler, S. M.; Sutton, J. C.; Treuner, U.; Zahler, R.; Zhao, G.; Bisacchi, G. *Bioorg Med Chem Lett* 2002, 12, 3235–3228.
- [17] Tanaka, A.; Sakai, H.; Motoyama, Y.; Ishikawa, T.; Takasugi, H. *J Med Chem* 1994, 37, 1189–1199.
- [18] Hammar, W. J.; Conway, A. C. *Riker Laboratories, Inc.* (1975) *Ger. Offen.* 2,410,982 (Cl. C 07d) *Chem Abst* 1975, 82, 4308x.
- [19] Tiwari, S. S.; Pandey, M. P.; *Indian J Chem* 1979, 188, 379–381.
- [20] Bruno, A. M.; Asis, S. E.; Goazza, C. H. *Pharmazie* 2001, 56, 361–365.
- [21] Renhowe, P. A. In *Annual Reports in Medicinal Chemistry*, Doherty, A. M. (Ed.); Academic: New York, vol. 35, 2001; 109–118.
- [22] van Steen, B. J.; van Wijngaarden, I.; Ronken, E.; Soudijn, W. *Bioorg Med Chem Lett* 1998, 8, 2475–2462.
- [23] Terán, C.; Santna, L.; Uriarte, E.; Fall, Y.; Unelius, L.; Tolf, B.-R. *Bioorg Med Chem Lett* 1998, 8, 3567–3570.
- [24] Tsukuda, T.; Shiratori, Y.; Watanabe, M.; Ontsuka, H.; Hattori, K.; Shirai, M. *Bioorg Med Chem Lett* 1998, 8, 1819, 1824.
- [25] Al-Soud, Y. A.; Wirschum, Hassan, N. A.; Maier, G.; Jochims, J. C. *Synthesis* 1998, 721–728 and references cited therein.
- [26] Benzing, E. *Liebigs Ann Chem* 1960, 631, 1–9.
- [27] Benzing, E. *Liebigs Ann Chem* 1960, 631, 10–21.
- [28] Al-Masoudi, N. A.; Hassan, N. A.; Al-Soud, Y. A.; Schmidt, P.; Gaafer, A. E.-D. M.; Weng, M.; Marino, S.; Schoch, A.; Amer, A.; Jochims, J. C. *J Chem Soc, Perkin Trans 1* 1998, 947–953.
- [29] Al-Soud, Y. A.; Al-Masoudi, W. A.; El-Halawa, R. A.; Al-Masoudi, N. A. *Nucleosides Nucleotides* 1999, 18, 1985–1994.
- [30] Al-Masoudi, N. A.; Al-Soud, Y. A.; Geyer, Y. A. *Tetrahedron* 1999, 55, 751–758.
- [31] Al-Soud, Y. A.; Al-Masoudi, N. A. *Arch Pharm Pharm Med Chem* 1999, 332, 143–144.
- [32] Al-Soud, Y. A.; Al-Masoudi, N. A. *Pharmazie* 2001, 56, 372–375.
- [33] Al-Soud, Y. A.; Al-Masoudi, N. A.; Lagoja, I. M. *Carbohydr Res* 1999, 318, 67–74.
- [34] Al-Soud, Y. A.; Halah, R. F.; Al-Masoudi, N. A. *Org Prep Proced Int (OPPI)* 2002, 34, 648–664.
- [35] Al-Soud, Y. A.; Al-Masoudi, N. A.; Ferwanah, A. E.-R. S. *Bioorg Med Chem* 2003, 11, 1701–1708.
- [36] Al-Soud, Y. A.; Al-Masoudi, N. A. *Heteroatom Chem* 2003, 14, 298–303.
- [37] Al-Soud, Y. A.; Al-Masoudi, N. A. *Farmaco* 2004, 59, 41–46.
- [38] Al-Soud, Y. A.; Al-Dweri, M. N.; Al-Masoudi, N. A. *Farmaco*, 2004, 59, 775–783.
- [39] Wang, Q.; Jochims, J. C.; St. Köhlbrandt, S.; Dahlenburg, L.; Al-Talib, M.; Hamed, A.; Ismail, A. E. *Synthesis* 1992, 710–718.
- [40] Wang, Q.; Al-Talib, M.; Jochims, J. C. *Chem Ber* 1994, 127, 541–547.
- [41] Willker, W.; Leibfritz, D.; Kerssebaum, R.; Bermel, W. *Magn Reson Chem* 1993, 31, 287–292, and reference therein.